SI1370243T1 - Postopek za pridobivanje mikrodelcev, ki vsebujejo inhibitor H+,K+-ATPaze - Google Patents

Postopek za pridobivanje mikrodelcev, ki vsebujejo inhibitor H+,K+-ATPaze

Info

Publication number
SI1370243T1
SI1370243T1 SI200230729T SI200230729T SI1370243T1 SI 1370243 T1 SI1370243 T1 SI 1370243T1 SI 200230729 T SI200230729 T SI 200230729T SI 200230729 T SI200230729 T SI 200230729T SI 1370243 T1 SI1370243 T1 SI 1370243T1
Authority
SI
Slovenia
Prior art keywords
sup
atp
ase inhibitor
microparticles containing
obtain microparticles
Prior art date
Application number
SI200230729T
Other languages
English (en)
Slovenian (sl)
Inventor
Hakan Glad
Malin Soderbom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1370243T1 publication Critical patent/SI1370243T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)
SI200230729T 2001-03-09 2002-03-06 Postopek za pridobivanje mikrodelcev, ki vsebujejo inhibitor H+,K+-ATPaze SI1370243T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles
PCT/SE2002/000400 WO2002072071A1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
EP02701872A EP1370243B1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor

Publications (1)

Publication Number Publication Date
SI1370243T1 true SI1370243T1 (sl) 2008-12-31

Family

ID=20283293

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230729T SI1370243T1 (sl) 2001-03-09 2002-03-06 Postopek za pridobivanje mikrodelcev, ki vsebujejo inhibitor H+,K+-ATPaze

Country Status (21)

Country Link
US (2) US20040101565A1 (https=)
EP (1) EP1370243B1 (https=)
JP (1) JP2004522796A (https=)
KR (1) KR20030081506A (https=)
CN (1) CN1507343A (https=)
AT (1) ATE400253T1 (https=)
AU (1) AU2002235101B8 (https=)
BR (1) BR0207827A (https=)
CA (1) CA2440163A1 (https=)
DE (1) DE60227488D1 (https=)
DK (1) DK1370243T3 (https=)
ES (1) ES2307722T3 (https=)
IL (1) IL157467A0 (https=)
MX (1) MXPA03007887A (https=)
NO (1) NO20033966L (https=)
NZ (1) NZ527997A (https=)
PT (1) PT1370243E (https=)
SE (1) SE0100822D0 (https=)
SI (1) SI1370243T1 (https=)
WO (1) WO2002072071A1 (https=)
ZA (1) ZA200306614B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2518780C (en) 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
US20070207266A1 (en) * 2006-02-15 2007-09-06 Lemke Harald K Method and apparatus for coating particulates utilizing physical vapor deposition
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US20090087569A1 (en) * 2007-09-27 2009-04-02 Fenchem Enterprises Ltd. Methods for Preparing Highly Stable Hyaluronic Acid
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20230058473A1 (en) * 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3565475D1 (en) * 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE3909455A1 (de) * 1989-03-22 1990-09-27 Hoechst Ag Verfahren zur herstellung von wasserdispergierbaren granulaten
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
DE19733094A1 (de) * 1997-07-31 1999-02-04 Merck Patent Gmbh Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität
ATE346589T1 (de) * 1997-10-15 2006-12-15 Merck Patent Gmbh Herstellung eines direkt verpressbaren tablettierhilfsstoffes
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ATE500815T1 (de) * 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles

Also Published As

Publication number Publication date
US20080175917A1 (en) 2008-07-24
BR0207827A (pt) 2004-03-02
PT1370243E (pt) 2008-09-16
CA2440163A1 (en) 2002-09-19
SE0100822D0 (sv) 2001-03-09
WO2002072071A1 (en) 2002-09-19
AU2002235101B8 (en) 2006-08-31
ES2307722T3 (es) 2008-12-01
NO20033966L (no) 2003-11-03
JP2004522796A (ja) 2004-07-29
CN1507343A (zh) 2004-06-23
US20040101565A1 (en) 2004-05-27
ZA200306614B (en) 2004-11-25
IL157467A0 (en) 2004-03-28
MXPA03007887A (es) 2003-12-04
DK1370243T3 (da) 2008-10-13
EP1370243A1 (en) 2003-12-17
ATE400253T1 (de) 2008-07-15
NZ527997A (en) 2005-02-25
HK1059896A1 (en) 2004-07-23
EP1370243B1 (en) 2008-07-09
DE60227488D1 (de) 2008-08-21
KR20030081506A (ko) 2003-10-17
AU2002235101B2 (en) 2006-07-13
NO20033966D0 (no) 2003-09-08

Similar Documents

Publication Publication Date Title
ZA200306614B (en) Method to obtain microparticles containing a H +, K + -ATP-ase inhibitor.
ATE365547T1 (de) Sprühgetrocknete proteinformulierungen
DK459486A (da) Vitaminholdigt granulat, fremstilling deraf og tabletter fremstillet deraf
AU7119500A (en) Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
AU8142594A (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
AU2623095A (en) Piperazine derivatives as 5ht1a antagonists
WO2003032953A1 (en) Granules containing acid-unstable chemical in large amount
MXPA03009284A (es) Una formulacion reguladora del crecimiento de la planta granular, soluble en agua, concentrada y metodos para utilizar la misma.
EP0931788A3 (en) Metalloprotease inhibitors
MX250472B (es) Granulos o polvo para la produccion de agentes de recubrimiento y aglutinantes para formas farmaceuticas.
PL349426A1 (en) Compositions comprising 1,1,1,3,3-pentafluorobutane and use of said compositions
CA2127876A1 (en) Imidazole derivatives and their use as cytokine inhibitors
MXPA04000849A (es) Composicion cristalina que contiene escitalopram.
NO20033967D0 (no) Fremgangsmåte for fremstilling av mikropartikler som inneholder metoprolol
AU8770301A (en) Process for the preparation of granules of methionine
AU2003234240A1 (en) Pharmaceutical composition containing lamotrigine particles of defined morphology
AP2000001837A0 (en) Pharmaceutical compositions containing micronized bicyclic drugs.
AU2003213661A8 (en) Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
MXPA04003892A (es) Proceso para produccion de granulos de detergente.
WO2002051399A3 (en) Divalproex sodium dosage forms and a process for their production
JP2001192330A5 (https=)
DE60009889D1 (de) Gipsverzögererzusammensetzung